| Name | Title | Contact Details |
|---|
Westerner Park is a Red Deer, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Veristat, a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.
Bp Solvay Polyethylene is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FYZICAL is the world`s fastest growing healthcare franchise, leading the charge to transform healthcare from one of “sick care” to “well care” by providing services focused on quality outcomes, total well-being, and prevention. FYZICAL provides business instruments allowing you to run your business more successfully and more profitably, immediately. Using a Nobel Prize winning formula, elite PTs, medical professionals, and business experts have created an innovative new business model which not only sets the standard for excellence in patient care, but also allows you to become the dominant provider of health care services in your community and secure a successful future. FYZICAL is effecting real change in healthcare by servicing a major unmet need in the patient population allowing independent business owners (financiers, PTs, Audiologists and Otolaryngologists) to experience emotional and financial rewards in the process.
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics.